Results 121 to 130 of about 4,022 (166)
Some of the next articles are maybe not open access.
Cefiderocol: A Siderophore Cephalosporin
Annals of Pharmacotherapy, 2020Objective: This article reviews the available data on the chemistry, spectrum of activity, pharmacokinetic and pharmacodynamic properties, clinical efficacy, and potential place in therapy of cefiderocol. Data Sources: A literature ...
Rania M. El-Lababidi, John George Rizk
openaire +2 more sources
Rapid cefiderocol NP test for detection of cefiderocol susceptibility/resistance in Enterobacterales
Journal of Antimicrobial Chemotherapy, 2022Abstract Background Cefiderocol is among the latest generation of commercialized antibiotics against a large variety of MDR Gram-negative bacteria including carbapenem-resistant Enterobacterales and non-fermenters such as Pseudomonas aeruginosa and Acinetobacter baumannii.
Patrice Nordmann +3 more
openaire +2 more sources
In a Pinch: Cefiderocol for CRAB Infections
Antimicrobial Agents and Chemotherapy, 2022Carbapenem-resistant Acinetobacter baumannii (CRAB) can cause significant infections with limited treatment options available. Falcone et al. ( https://doi.org/10.1128/aac.02142-21 ) describe a single-center retrospective study comparing clinical outcomes among patients with CRAB infections ...
Sara M. Karaba +2 more
openaire +2 more sources
Cefiderocol: a novel siderophore cephalosporin
Expert Opinion on Investigational Drugs, 2018The emergence of multidrug-resistant bacterial pathogens has led to a global public health emergency and novel therapeutic options and drug-delivery systems are urgently needed. Cefiderocol is a siderophore cephalosporin antibiotic that has recently been developed to combat a variety of bacterial pathogens, including β-lactam- and carbapenem-resistant ...
Justin J, Choi, Matthew W, McCarthy
openaire +2 more sources